Our dedicated team is well established and experienced in the delivery of clinical trials with a diverse portfolio of more than 50 active trials.

Our team consists of principal investigators, research nurses and clinical trial coordinators who are responsible for the management and delivery of each clinical trial.

With interests in clinical and translational research, our researchers work on a variety of national and international clinical trials and are recognised as international experts in their field.  Over the last few years we have been the only site in the Greater Manchester area to offer clinical trials in certain targeted therapies

We currently have clinical trials, including transplant trials, in most haematological malignancies (leukaemias, myeloma, myeloproliferative neoplasms) and lymphomas.

As well as our larger phase 2, 3 and 4 trials, we deliver phase 1 first-in-human trials. Some of these trials are available to rarer indications, meaning that we are able to offer treatment across the wider disease group.

We also have relationships with non-commercial and commercial partners, meaning we are often informed of new treatments that are being developed. This allows investigators to contribute to the development of protocols and the design of clinical trials.

We have strong links with hospitals in the region and across the UK, giving patients more access to clinical trials and treatments. Most of our patients are identified through referrals, with over 500 referrals received per year. Around 30 per cent of our referrals are considered for participation in a clinical trial with approximately 20 per cent of patients enrolled.

We are happy to receive referrals for consideration of clinical trials and/or second opinions for anywhere in the UK.


  • First centre in the UK to open a clinical trial for a new treatment for leukaemia. This was a first-in-human clinical trial and the drug used was developed at the CRUK Manchester Institute.
  • A pivotal role in a practice-changing clinical trial for early-stage Hodgkin lymphoma. This trial showed that PET scanning can be used to identify patients with this disease who do not require radiotherapy after chemotherapy. As a result, guidelines are being amended worldwide
  • Involvement in trials in both lymphoma and chronic lymphocytic leukaemia which led to ibrutinib obtaining an FDA licence and being added to the cancer drugs fund list in the UK
  • Part of a prestigious international research collaboration in cutaneous lymphoma. We are one of only three centres participating in two international phase 3 trials in this indication
  • Highest UK recruiter for a number of clinical trials, including a commercial trial for a vaccine against herpes zoster after transplant for haematology and lymphoma indications; and a commercial phase 3 trial looking at new treatments in CD20+ DLBCL (diffuse large B-Cell lymphoma)
  • Highest recruiter globally in a commercial observational cohort study looking at the safety of brentuximab vedotin in relapsed/refractory CD30+ Hodgkin lymphoma and sALCL (anaplastic large cell lymphoma)

Team objectives

  • To increase the treatment choices available to Christie patients
  • To recruit and retain quality clinical researchers and leaders to further develop Manchester as an international leader in research for patients with haematological malignancies
  • To maintain a portfolio where a clinical trial can be offered to every patient alongside conventional treatment at every point in their treatment journey
  • To promote informed decisions by patients in their treatment pathways and increase awareness of clinical trial options by involvement in international clinical trials day, educational events and website development